ALLMedicine™ Paronychia Center

May 10th, 2022 - Practice Essentials Paronychia is a soft tissue infection around a fingernail or toenail that begins as cellulitis but that may progress to a definite abscess. [1] The 2 types of paronychia are as follows [2] : Acute paronychia - Painful and purul...

May 10th, 2022 - Approach Considerations The treatment of choice depends on the extent of the infection. If diagnosed early, acute paronychia without obvious abscess can be treated nonsurgically. If soft tissue swelling is present without fluctuance, the infection...

Apr 14th, 2022 - Usefulness of Noninvasive Management With the Gutter Method for Epidermal Growth Factor Receptor Inhibitor-Induced Paronychia, Pyogenic Granuloma-Like Lesion, and Ingrown Nail.|2022|Agematsu A,Kamata M,Namiki K,Yabuuchi Y,Nagata M,|

Mar 17th, 2022 - Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the first-line treatment for EGFR-mutant non-small cell lung cancer. Toxicities related to EGFR-TKIs include skin rash, paronychia, and diarrhea, which in some...

Jan 21st, 2022 - EGFR pathway inhibition may promote anti-programmed cell death protein 1 (PD-1) responses in preclinical models, but how EGFR inhibition affects tumor antigen presentation during anti-PD-1 monotherapy in humans remain unknown. We hypothesized that...

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

Sep 17th, 2019 - Nails are characteristically affected in skin diseases such as psoriasis (speckling, psoriatic oil spot, crumbling nails, pachyonychia) ,lichen( anonychia, dystrophy) ,alopecia areata (speckling, trachyonychia, longitudinal grooves, leukonychia), ...

Feb 10th, 2017 - Epidermal growth factor receptor(EGFR) is involved in cell proliferation and is overexpressed or abnormally activated in malignant tumors originating from the colon, breast, ovary, pancreas, and lung. EGFR tyrosine kinase inhibitor(TKI), gefitinib...

Oct 27th, 2021 - Transcript: Erminia Massarelli, MD, MS, PhD: The mechanism of action of mobocertinib [Exkivity] is an irreversible EGFR tyrosine kinase inhibitor. However, it differs from osimertinib [Tagrisso], which is currently approved for exon 19 and21 muta...

Sep 29th, 2021 - Once-daily dosing of poziotinib shows clinically meaningful efficacy for patients with treatment-naive non–small cell lung cancer (NSCLC) HER2 exon 20 mutations, according to results of the ZENITH20 trial presented at the 2021 European Society for...

Sep 24th, 2021 - When Haiying Cheng, MD, PhD, was testing a plastic tent for the first-inhuman trial of inhaled azacitidine to treat patients with advanced non–small cell lung cancer (NSCLC), she had an unusual subject zero: Roman Perez-Soler, MD, the highly accom...

Aug 24th, 2021 - Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies, while damage to other nail unit anatomic areas can be wide-ranging. Those are key findings from an evi.

Aug 24th, 2021 - Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies, while damage to other nail unit anatomic areas can be wide-ranging. Those are key findings from an evi...